Theravance Biopharma (TBPH) Misses Q1 EPS by 5c, Beats on Revenue

Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.27), $0.05 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.14 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Unifor starts contract talks with Ford for 5,150 workers
• OpenAI launches cybersecurity tools and open-source patching program